Literature DB >> 11212268

Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.

P M Thompson1, J M Maris, M D Hogarty, R C Seeger, C P Reynolds, G M Brodeur, P S White.   

Abstract

Loss of heterozygosity of several specific genomic regions is frequently observed in neuroblastoma tumors and cell lines, but homozygous deletion (HD) is rare, and no neuroblastoma tumor suppressor gene (TSG) has yet been identified. We performed a systematic search for HD, indicative of a disrupted TSG, in a panel of 46 neuroblastoma cell lines. An initial search focused on a well-characterized consensus region of hemizygous deletion at 1p36.3, which occurs in 35% of primary neuroblastomas. Each cell line was screened with 162 1p36 markers, for a resolution of 13 kb within the consensus 1p36.3 deletion region and 350 kb throughout the remainder of 1p36. No HDs were detected. This approach was expanded to survey 21 known TSGs, specifically targeting intragenic regions frequently inactivated in other malignancies. HD was detected only at the CDKN2A (p16INK4a/p14ARF) gene at 9p21 and was observed in 4 of 46 cell lines. The observed region of HD included all exons of both CDKN2A and the closely linked CDKN2B (p15INK4b) gene for cell lines LA-N-6 and CHLA-174, all exons of CDKN2A but none of CDKN2B for CHLA-179, and only 104 bp within CDKN2A exon 2 for CHLA-101. All four deletions are predicted to inactivate the coding regions of both p16INK4a and p14ARF. HD was observed in corresponding primary tumor samples for CHLA-101 and CHLA-174 but was not present in constitutional samples. These results suggest that for neuroblastoma, large HDs do not occur within 1p36, most known TSGs are not homozygously deleted, and biallelic inactivation of CDKN2A may contribute to tumorigenicity in a subset of cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212268

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Signaling from p53 to NF-kappa B determines the chemotherapy responsiveness of neuroblastoma.

Authors:  Michael B Armstrong; Xin Bian; Yihong Liu; Chitra Subramanian; Anthony B Ratanaproeksa; Feng Shao; Victor C Yu; Roland P S Kwok; Anthony W Opipari; Valerie P Castle
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

2.  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.

Authors:  Jane Carr-Wilkinson; Kieran O'Toole; Katrina M Wood; Christine C Challen; Angela G Baker; Julian R Board; Laura Evans; Michael Cole; Nai-Kong V Cheung; Joachim Boos; Gabriele Köhler; Ivo Leuschner; Andrew D J Pearson; John Lunec; Deborah A Tweddle
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

3.  Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.

Authors:  Ahsan S Farooqi; Rebecca A Dagg; L Mi Rim Choi; Jerry W Shay; C Patrick Reynolds; Loretta M S Lau
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

4.  Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma.

Authors:  Jinesh S Gheeya; Qing-Rong Chen; Christopher D Benjamin; Adam T Cheuk; Patricia Tsang; Joon-Yong Chung; Belhu B Metaferia; Thomas C Badgett; Peter Johansson; Jun S Wei; Stephen M Hewitt; Javed Khan
Journal:  Cancer Biol Ther       Date:  2009-12-27       Impact factor: 4.742

5.  ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.

Authors:  Michael D Hogarty; Murray D Norris; Kimberly Davis; Xueyuan Liu; Nicholas F Evageliou; Candace S Hayes; Bruce Pawel; Rong Guo; Huaqing Zhao; Eric Sekyere; Joanna Keating; Wayne Thomas; Ngan Ching Cheng; Jayne Murray; Janice Smith; Rosemary Sutton; Nicola Venn; Wendy B London; Allen Buxton; Susan K Gilmour; Glenn M Marshall; Michelle Haber
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

6.  Effects of exogenous p16(ink4a) gene on biological behaviors of human lung cancer cells.

Authors:  Xiaoju Zhang; Yang Jin; Xiaonan Tao; Ming Bai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-02

7.  Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data.

Authors:  Filip Kramar; Zuzana Zemanova; Kyra Michalova; Libuse Babicka; Sarka Ransdorfova; Petr Hrabal; Petr Kozler
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

Review 8.  ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

Authors:  S Ries; W M Korn
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

9.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

10.  Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours.

Authors:  J Mora; M Alaminos; C de Torres; P Illei; J Qin; N-K V Cheung; W L Gerald
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.